Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis

Table 4 Characteristics of patients who developed herpes zoster

Case	Age	Sex	Prior TNF-α failure	TOF dose (mg/day)	Week of onset	pMS at onset	Lymphocyte count (/μL)	Concomitant drug	Therapy for HZ	TOF therapy	Area of HZ	Postherpetic neuralgia
1	68	F	(+)	10	30	1	1362	5ASA; PPI; ARB	OAD	Continuation	Lower leg	(+)
2	30	F	(+)	20	5	0	1570	Prednisolone 10 mg	OAD	Resumption after drug withdrawal	Head; Neck; Back	(-)
3	25	F	(+)	10	23	1	1102	5ASA	OAD	Continuation	Back	(-)
4	48	M	(+)	10	31	1	1810	5ASA	OAD	Resumption after drug withdrawal	Abdomen	(-)
5	54	F	(-)	20	5	1	2127	Iron preparations	OAD	Discontinuation	Buttocks	(-)
6	53	M	(+)	10	26	0	922	(-)	OAD	Continuation	Back	(-)

5ASA: 5-aminosalicylate; ARB: Angiotensin II receptor blocker; HZ: Herpes zoster; OAD: Oral antiviral drug; pMS: Partial Mayo Score; PPI: Proton pump inhibitor; TNF-α: Tumor necrosis factor α; TOF: Tofacitinib.